Pomalidomide
Found 8 free book(s)
MEDICATION GUIDE - media.celgene.com
media.celgene.comMEDICATION GUIDE POMALYST® (POM-uh-list) (pomalidomide) capsules What is the most important information I should know about POMALYST? Before you begin taking POMALYST, you must read and agree to all of the instructions in the POMALYST REMS®
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBCCA HD List . abiraterone1 enzalutamide1 PACLitaxel1 acitretin3 epirubicin1 PACLitaxel, nab4 AFAtinib1 eriBULin1 palbociclib4 alectinib4 erlotinib1 pamidronate3 amsacrine1 estramustine1 PAZOPanib1 anastrozole1 etoposide1 pemetrexed1 arsenic trioxide 1 everolimus1 PERTuzumab1 atezolizumab4 exemestane1 plerixafor3 avelumab4 pomalidomide1 aXitinib1 PONATtinib1 azaCITIDine1 fludarabine1 procarbazine1
Harzardous Drug Medication List *COLOR CODE AND PPE KEY
aspiruslibrary.orgCepastat lozenge N/ABlack EPA Cerubidine N/ABlack EPA Cetacaine aerosol N/ABlack Trash EPA Cetrorelix Blue Trash Yellow NIOSH Chloral hydrate syrup N/ABlack EPA Chlorambucil tablet Black Yellow NIOSH Chloramphenicol Blue Trash Yellow NIOSH Chorhexidine gluconate solution N/ABlack Trash EPA Choriogonadotropin Blue Trash Yellow NIOSH Cidofovir Blue Trash Yellow NIOSH ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
media.celgene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use POMALYSTsafely and effectively. See full prescribing information for
OUR CLINICAL TRIALS - Amgen Oncology
www.amgenoncology.comInformation as of 4/1/2016. Statements are based on the company’s current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen’s filings with the SEC.
OUR CLINICAL TRIALS - Amgen Oncology
www.amgenoncology.com*For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgentrials.com. †The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification.
付表ⅠE 指定を受けた医薬品の有効成分（4回目の見直しによる追加）
www.customs.go.jp号(Sub-heading) 品 名 Description 2842.90 フェルマガート fermagate 2843.90 パデリポルフィン padeliporfin 2844.40 ヨードフィルト酸(123Ⅰ) iodofiltic acid (123I)
Dexamethasone 4 mg tablets - Medicines
www.medicines.org.ukPACKAGE LEAFLET: INFORMATION FOR THE USER Dexamethasone 4 mg tablets Dexamethasone Read all of this leaflet carefully before you start taking this medicine because it contains important